DexCom, Inc. $DXCM Stock Holdings Increased by Norinchukin Bank The

Key Points

• Norinchukin Bank increased its stake in DexCom, Inc. by 43.6% during Q1, acquiring an additional 9,608 shares, bringing its total holdings to 31,648 shares valued at approximately $2.16 million.
• DexCom recently reported earnings of $0.48 per share, beating estimates by $0.03, and a revenue of $1.16 billion, reflecting a year-over-year increase of 15.2%.
• Analysts have given DexCom an average rating of "Moderate Buy" with a price target of approximately $99.89, reflecting their positive outlook on the company’s future performance.

Norinchukin Bank The lifted its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 43.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 31,648 shares of the medical device company's stock after buying an additional 9,608 shares during the quarter. Norinchukin Bank The's holdings in DexCom were worth $2,161,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of DXCM. Golden State Wealth Management LLC lifted its position in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the last quarter. Zions Bancorporation National Association UT bought a new position in shares of DexCom in the 1st quarter worth about $27,000. Optiver Holding B.V. bought a new position in shares of DexCom in the 4th quarter worth about $33,000. Heck Capital Advisors LLC bought a new position in shares of DexCom in the 4th quarter worth about $38,000. Finally, Alpine Bank Wealth Management bought a new position in shares of DexCom in the 1st quarter worth about $40,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

DexCom stock traded up $0.26 during midday trading on Wednesday, reaching $76.38. 3,662,744 shares of the stock traded hands, compared to its average volume of 3,892,372. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a fifty day moving average price of $82.56 and a two-hundred day moving average price of $79.66. The firm has a market cap of $29.95 billion, a price-to-earnings ratio of 53.04, a PEG ratio of 1.59 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm earned $0.43 EPS. DexCom's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling at DexCom

In related news, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director directly owned 33,411 shares in the company, valued at $2,766,430.80. The trade was a 9.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,722 shares of company stock valued at $1,306,131 over the last quarter. Company insiders own 0.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DXCM shares. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Raymond James Financial raised their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. William Blair upgraded shares of DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group initiated coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.